All In Biotech

Drug Trial Radar · NCT02969655

A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)

A 52-week, Phase III, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Currently ESA Users

Last checked: Nov 19, 2026Latest source record: Nov 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 271 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

271

Actual

Start

Nov 21, 2016

Primary completion

Jul 2, 2018

Study completion Jul 2, 2018

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 21, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Daprodustat is a drug that is currently being developed as a treatment for renal anemia . This study is to evaluate the efficacy and safety of daprodustat following a switch from erythropoiesis-stimulating agent (ESA) in Japanese HD subjects with renal anemia who are currently treated with ESA. The primary objective is to demonstrate non-inferiority of daprodustat to darbepoetin alfa. This study is a 52-week, Phase III, double-blind, active-controlled, parallel-group, multi-center study. The total duration of the study will be approximately 58 weeks including screening and follow-up.

Conditions

  • Anaemia

Interventions

  • Daprodustat smallDrug

    Available as 7.0 millimeter (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of daprodustat as active ingredient

  • Daprodustat small placeboDrug

    Available as 7.0 mm round, standard biconvex, white film coated tablets containing no daprodustat

  • Daprodustat largeDrug

    Available as 9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of daprodustat as active ingredient

  • Daprodustat large placeboDrug

    Available as 9.0 mm round, standard biconvex, white film coated tablets containing no daprodustat

  • Darbepoetin alfaDrug

    Available as 0.5 mL plastic prefilled syringes (PFS) for IV injection each containing 10, 15, 20, 30, 40 or 60 mcg of darbepoetin alfa in a clear and colorless solution.

  • Darbepoetin alfa placeboDrug

    Available as 0.5 mL plastic PFS for IV injection containing no darbepoetin alfa in a clear and colorless solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Hemoglobin (Hgb) During the Primary Efficacy Evaluation Period (Weeks 40 to 52)Time frame: Weeks 40 to 52

Locations

50 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Aichi, Japan

  • GSK Investigational Site

    Aichi, Japan

  • GSK Investigational Site

    Aichi, Japan

  • GSK Investigational Site

    Aichi, Japan

  • GSK Investigational Site

    Aichi, Japan

  • GSK Investigational Site

    Aichi, Japan

  • GSK Investigational Site

    Aichi, Japan

  • GSK Investigational Site

    Chiba, Japan

  • GSK Investigational Site

    Ehime, Japan

  • GSK Investigational Site

    Ehime, Japan

  • GSK Investigational Site

    Fukui, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Fukushima, Japan

  • GSK Investigational Site

    Fukushima, Japan

  • GSK Investigational Site

    Gunma, Japan

  • GSK Investigational Site

    Gunma, Japan

  • GSK Investigational Site

    Gunma, Japan

  • GSK Investigational Site

    Hokkaido, Japan

  • GSK Investigational Site

    Hokkaido, Japan

  • GSK Investigational Site

    Hokkaido, Japan

  • GSK Investigational Site

    Hokkaido, Japan

  • GSK Investigational Site

    Ibaraki, Japan

  • GSK Investigational Site

    Ibaraki, Japan

  • GSK Investigational Site

    Ibaraki, Japan

  • GSK Investigational Site

    Kagawa, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Kanagawa, Japan

  • GSK Investigational Site

    Kyoto, Japan

  • GSK Investigational Site

    Miyagi, Japan

  • GSK Investigational Site

    Nagano, Japan

  • GSK Investigational Site

    Nagano, Japan

  • GSK Investigational Site

    Nagano, Japan

  • GSK Investigational Site

    Okayama, Japan

  • GSK Investigational Site

    Osaka, Japan

  • GSK Investigational Site

    Osaka, Japan

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.